help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 7, 765-773, July 2006; doi:10.1634/theoncologist.11-7-765
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Pat...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, J. R.
Right arrow Articles by Welsh, K. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ross, J. R.
Right arrow Articles by Welsh, K. I.

Clinical Pharmacology

Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Patients

Joy R. Rossa,b, Julia Rileya, Columba Quigleyc, Ken I. Welshb

a Department of Palliative Medicine, Royal Marsden Hospital, London, United Kingdom; b Department of Clinical Genomics, Imperial College, London, United Kingdom; c Cancer Centre, Hammersmith Hospital, London, United Kingdom

Key Words. Cancer • Opioid • Switching • Polymorphism

Correspondence: Joy R. Ross, M.D., Department of Palliative Medicine, Horder Ward, Royal Marsden Hospital, London SW3 6JJ, United Kingdom. Telephone: 0207-808-2761; Fax: 0207-808-2478; e-mail: joy.ross{at}rmh.nhs.uk

Pain is one of the most common and often most feared symptoms in patients with cancer. Ongoing or progressive pain is physically debilitating and has a marked impact on quality of life. Since a third of the population will die from cancer, and of these, 80% will experience severe pain in their final year of life, effective treatment of cancer-related pain remains both a high priority and an ongoing challenge in clinical practice. Individuals with moderate to severe cancer-related pain require treatment with strong analgesics, namely opioids.

There is evidence to support the therapeutic maneuver of opioid switching in clinical practice, but further evidence is needed to elucidate the underlying mechanisms for interindividual differences in response to different opioids. Large, robust clinical trials will be needed if clinical differences among side-effect profiles of different opioids are to be clearly demonstrated. This review discusses candidate genes, which contribute to opioid response; many other genes have also been implicated in "pain" from animal or human studies. In order to continue to evaluate the genetic contributions to both pain susceptibility and analgesic response, further candidate genes need to be considered. Good pain control remains a high priority for clinicians and patients, and there is much work to be done to further individualize analgesic therapy for patients with cancer.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
H. Ahdieh and R. White
Comment: Oral Oxymorphone for Pain Management
Ann. Pharmacother., December 1, 2007; 41(12): 2074 - 2074.
[Full Text] [PDF]

Home page
 Palliat MedHome page
S. Kay, E. Husbands, J.H. Antrobus, and D. Munday
Provision for advanced pain management techniques in adult palliative care: a national survey of anaesthetic pain specialists
Palliative Medicine, June 1, 2007; 21(4): 279 - 284.
[Abstract] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2006 by AlphaMed Press.